Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.

A new antibody therapy clears pre-leukemia in some blood cancer patients while causing mostly mild side effects, expanding treatment options beyond chemotherapy.

CD123/CD3 bispecific antibody vibecotamab achieved 19% MRD clearance in AML-MRD cohort and 67% ORR in MDS/CMML after HMA failure (n=48, MD Anderson); CRS was common (60%) but predominantly grade 1-2, supporting CD123-targeting bispecifics as a viable strategy in low-blast myeloid diseases.

What the study was

Study design

phase_2_trial

Category

hematologic_malignancies

Maturity

clinical

Journal

Journal of Hematology & Oncology

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.